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Abstract
Background: Ovarian cancer is usually diagnosed at a late stage when outcomes are poor. Personalised ovarian cancer
risk prediction, based on genetic and epidemiological information and risk stratified management in adult women could
improve outcomes. Examining health care professionals’ (HCP) attitudes to ovarian cancer risk stratified management,
willingness to support women, self-efficacy (belief in one’s own ability to successfully complete a task), and knowledge
about ovarian cancer will help identify training needs in anticipation of personalised ovarian cancer risk prediction being
introduced.
Methods: An anonymous survey was distributed online to HCPs via relevant professional organisations in the UK. Kruskal-
Wallis tests and pairwise comparisons were used to compare knowledge and self-efficacy scores between different types
of HCPs, and attitudes toward population-based genetic testing and risk stratified management were described. Content
analysis was undertaken of free text responses concerning HCPs willingness to discuss risk management options with
women.
Results: One hundred forty-six eligible HCPs completed the survey: oncologists (31%); genetics clinicians (30%); general
practitioners (22%); gynaecologists (10%); nurses (4%); and ‘others’. Scores for knowledge of ovarian cancer and genetics,
and self-efficacy in conducting a cancer risk consultation were generally high but significantly lower for general
practitioners compared to genetics clinicians, oncologists, and gynaecologists. Support for population-based genetic
testing was not high (<50%). Attitudes towards ovarian cancer risk stratification were mixed, although the majority of
participants indicated a willingness to discuss management options with patients.
Conclusions: Larger samples are required to investigate attitudes to population-based genetic testing for ovarian
cancer risk and to establish why some HCPs are hesitant to offer testing to all adult female patients. If ovarian cancer
risk assessment using genetic testing and non-genetic information including epidemiological information is rolled out
on a population basis, training will be needed for HCPs in primary care to enable them to provide appropriate support
to women at each stage of the process.
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Background
Ovarian cancer is the sixth most common cancer among
women in the UK [1]. Due to the lack of distinctive symp-
toms, most women are diagnosed at a late stage when mor-
tality is high. Around 46% of women diagnosed with
ovarian cancer in England and Wales survive 5 years or
more; however, in the large proportion of women diag-
nosed with advanced stage disease, 5-year survival is only
10% [1]. Ovarian cancer screening within the general popu-
lation is currently not available on the National Health
Service (NHS) in the UK due to lack of definitive evidence
that it decreases mortality through early detection [2].
The strongest genetic risk factors for ovarian cancer are
mutations in the BRCA1/2 genes. Clinical genetic testing
for BRCA1/2 gene mutations is currently available as a ser-
vice on the NHS in the UK to individuals with a 10% or
greater chance of carrying a BRCA1/2 mutation [3] includ-
ing those with high grade non-mucinous ovarian cancer,
or those with a strong family history of breast and/or ovar-
ian cancer. Once a pathogenic mutation is identified, test-
ing can be offered to relatives to estimate their risk of
developing the disease and to identify the most appropriate
risk management strategy [4]. Approximately 10–15% of
ovarian cancer cases are believed to be due to a BRCA1/2
mutation [5, 6], however ~50% of individuals with a patho-
genic BRCA mutation may not report a strong family his-
tory of cancer [7, 8]. These families may not be referred to
clinical genetics even though current guidelines [9] recom-
mend testing in these situations. Population based genetic
testing could address this.
Progress in (1) scientific understanding of the genetic
basis of different sub-types of ovarian cancer, as well as (2)
the identification of common gene mutations that cumula-
tively may confer an increased risk, and (3) lower costs of
genetic testing, mean that population-based risk stratifica-
tion based on the combination of genetic and non-genetic
information (e.g. family history, lifestyle) could become a
viable option [10, 11]. The PROMISE research programme
(Predicting Risk of Ovarian Malignancies, Improving
Screening and Early detection, https://eveappeal.org.uk/
our-research/our-research-programmes/promise-2016/)
aims to improve early detection and risk management of
ovarian cancer. PROMISE includes a feasibility study for a
population-based risk stratified programme for ovarian
cancer, utilising genetic testing. Risk-management strat-
egies including information for those at low risk and
screening or risk-reducing surgery for those at intermedi-
ate and high risk will then be offered accordingly. This
population-based approach could improve early ovarian
cancer detection by flagging up high-risk individuals for
intensive screening, while reducing the number of un-
necessary investigations carried out on low-risk individuals
[12]. Recently published findings from the UK Familial
Ovarian Cancer Screening Study (UKFOCSS) indicate that
multimodal screening, involving 4-monthly blood tests for
biomarker CA125 interpreted with the risk of ovarian can-
cer algorithm (ROCA), and secondary testing with trans-
vaginal ultrasound, is highly sensitive and can detect
ovarian cancer at an earlier stage [13]. Whilst risk-
reducing surgery would still be the best option for women
at high risk of ovarian cancer, screening could be offered
to those who choose not to have surgery. The ability and
willingness of health care professionals (HCPs) to support
such a programme of population-based risk assessment
and stratified management [11] needs to be established be-
fore it could be rolled out in the UK.
Evidence from Europe and the US suggests that HCPs in
primary care generally have quite low levels of genetics
knowledge [14, 15] and lack confidence in their ability to
carry out tasks such as recording patients’ family histories
of disease, discussing the risks and benefits of genetic test-
ing and counselling patients about their test results [16–
18]. It is unsurprising to find that oncologists and gynae-
cologists are more knowledgeable about genetics than gen-
eral or family practitioners [19, 20]. It is encouraging to
note that HCPs who completed training more recently
appear to have more knowledge of genetics [21, 22], and
greater confidence in their ability to explain genetic test re-
sults than those who had been practising for over 20 years
[22]. HCPs’ knowledge and confidence in their ability to
provide appropriate information is important, as it may
influence referring behaviour [23]. However, there is little
recent research investigating UK HCPs’ knowledge of
cancer genetics or confidence in assessing cancer risk and
discussing genetic testing with patients.
While HCPs acknowledge that genetic testing can help
identify those at risk of potentially life-threatening dis-
eases, personalise interventions, indicate when to offer
screening and increase the ability to prevent certain can-
cers [15, 18, 24], several barriers have been identified [25,
26]. These include lack of time and clear referral and man-
agement guidelines [22, 24], as well as lack of clarity about
what an abnormal genetic test result might mean for an
individual patient’s cancer risk [25, 27]. Understandably,
physicians have expressed apprehension about discussing
genetic risk with patients if an effective treatment or inter-
vention is not available [15, 28]. There is concern that ad-
verse genetic test results might have a negative impact on
patients’ psychological well-being [17, 22, 25]. Further-
more, both HCPs and patients have concerns about po-
tential discrimination from insurers or employers
following a genetic test result indicating increased disease
risk [25, 27, 29].
This study aimed to investigate UK HCPs’ knowledge of
ovarian cancer genetics and other risk factors, as well as
self-efficacy (belief in one’s own ability to successfully
complete a task [30]) in discussing cancer risk and genetic
testing with patients, in order to identify professional
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training needs. Attitudes towards population-based gen-
etic testing and stratified risk management strategies for
ovarian cancer were also explored.
Methods
An anonymous cross-sectional online survey was devel-
oped using the software Opinio as an effective method of
reaching a convenience sample of HCPs [31]. This type of
non-probability sampling involves drawing the sample
from a readily available and convenient source of HCPs
via groups and networks to which we had easy access.
These included: British Gynaecological Cancer Society,
National Forum of Gynaecological Oncology Nurses; the
UK Cancer Genetics Group; Cancer, General Practice and
Genetics Clinical Research Networks, The Royal College
of General Practitioners; and the National Cancer
Research Institute. We also recruited participants by
‘snowballing’ using a list of researcher contacts. Potential
participants received an invitation from their professional
organisation either by email with a link to the online sur-
vey, or by a similarly worded advertisement in a web-
based professional news update. Some organisations sent
a reminder email or advertisement with a link to the sur-
vey approximately 1 month after the initial invitation. Par-
ticipants were eligible if they self-identified as a HCP
based in the UK and the survey had relevance to their
practice. HCPs who voluntarily accessed the survey, and
completed and submitted it, did so in the knowledge that
they were thereby giving consent for their anonymous re-
sponses to be included in the study. The participant infor-
mation preface to the online survey explained these steps
in the consent process and stated that since data was an-
onymous formal verbal or written consent was not re-
quired. The study was approved by UCL research ethics
committee (project ID: 8053/002) and was open to partici-
pants for 3 months from March 2016.
The survey items were generated with reference to the
literature on HCPs’ knowledge of and attitudes towards
genetic testing and were refined by the multidisciplinary
research team. A pilot was carried out in a sample of 6
HCPs and adjustments were made to the structure and
order of questions based on this pilot. Participants were
briefed about the PROMISE research programme to es-
tablish the context for this study, and questions were
framed in relation to population-based genetic testing and
risk stratification for women. (See Additional file 1 for the
full survey and information provided to participants.)
Knowledge of ovarian cancer and genetics was mea-
sured using five True/False/Not sure questions and three
multiple choice questions about the risk of ovarian can-
cer within (1) the general population and (2) those with
a BRCA1 or BRCA2 mutation. Correctly answered ques-
tions were added to give a score of 0–8. The measure
had adequate internal reliability (α = .691).
Seven items were included to assess HCPs’ self-efficacy
in conducting a clinical cancer risk consultation. A four-
point Likert-style response was used including the options
“not at all confident”, “somewhat confident”, “quite
confident” and “very confident”. Scores were produced by
calculating the average of the 7 items to give a score be-
tween 1 and 4, where a higher score indicates higher levels
of self-efficacy. The internal reliability was high for this
measure (α = .936).
HCPs’ attitudes (perceived benefits and risks) towards
hypothetical population-based genetic testing for ovarian
cancer risk were measured with 7 items. Beliefs about risk
stratification levels were explored with 3 items in which
participants were asked to indicate the level of lifetime
ovarian cancer risk (as a percentage) that you think is
‘low/intermediate/high risk’. Attitudes (perceived benefits
and risks) towards risk stratification were measured with
nine items after presenting the actual risk levels/thresholds
set for the PROMISE feasibility study (low risk = 0 to 4.9%
risk, intermediate risk = 5 to 9.9% risk, high risk = ≥10%
risk). Three items were used to establish participants’ self-
efficacy in communicating the stratified levels of risk. All
attitude items used a 5-point Likert-style response scale to
measure the extent to which participants agreed with each
statement (strongly disagree to strongly agree).
HCPs’ willingness to tailor patient management accord-
ing to risk was measured with 5 items, after presenting
participants with the recommended management options
from the PROMISE feasibility study. A 4-point Likert-
style response was provided for participants to indicate
their willingness (“yes, definitely” to “no, definitely not”).
Participants were also presented with optional open-
ended questions requesting further information on their
reasons for their decisions.
Background and demographic information was collected
on participants’ gender, age, ethnicity, current post, clinical
setting, years in post and year of graduation. Further ques-
tions were used to elicit: whether they had learnt about
genetic cancer risk during their training; how often they
were involved in any aspect of assessing risk for ovarian
and/or breast cancer; and whether they or any of their
close relatives had been diagnosed with, or had had a risk
assessment for, ovarian cancer or another cancer.
Frequencies were calculated for each item. Comparisons
were made between completers’ and non-completers’
knowledge and self-efficacy scores using non-parametric
Mann Whitney tests.
Participants were grouped by specialism: oncologists (in-
cluding medical, clinical and gynaecological oncologists
and oncology surgeons), cancer genetics clinicians (includ-
ing clinical geneticists and genetic counsellors), General
Practitioners (GPs) and gynaecologists. There were too
few participants who self-identified as nurse specialists or
‘other’ to include in statistical comparisons. Differences
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between the groups of HCPs regarding relevant knowledge
and self-efficacy to conduct a risk consultation were ex-
plored with Kruskal-Wallis tests and pairwise compari-
sons. Fisher’s exact tests compared HCPs’ willingness to
offer genetic testing for ovarian cancer risk to all adult
female patients after response categories were collapsed
into three: agree/strongly agree, neutral, and disagree/
strongly disagree. Bonferroni corrections were made for
multiple testing. All statistical analyses were carried out
using SPSS version 22.
Inductive content analysis [32] was performed on the
free text responses to open-ended questions concerning
participants’ willingness to discuss risk-management strat-
egies with patients. Analysis was conducted by two re-
searchers who independently read and made notes
alongside the data (KH & MF). Themes were identified
and a coding manual was produced. One researcher coded
all data (KH), and the second researcher independently
coded 10% of the data (MF). A Cohen’s κ calculation indi-
cated that agreement in coding between the two re-
searchers was substantial (according to Landis and Koch
[33]), κ = .744 (95% CI = .689 to .862), p < .001. Ambiguous
responses such as ‘as before’ or ‘as previous answer’ were
not included in the analysis.
Results
Sample characteristics
In total, 253 potential participants opened the survey
link and 149 (58.9%) completed the survey. Of the 149
participants who completed the survey, 3 were ineligible
as it was unclear if they were registered HCPs, produ-
cing a final sample size of 146 participants. Table 1
shows the demographic characteristics of the partici-
pants. The majority of participants indicated they had
Table 1 Participant characteristics (n = 146)
N (%)











Prefer not to say 8 (5.5)
Current post
General Practitioner 32 (21.9)
Genetics Specialist 44 (30.1)
Oncologist 45 (30.8)
Gynaecologist 15 (10.3)
Nurse specialist 6 (4.1)
Other 4 (2.7)
Years in post, Mean (SD) 11.7 (8.2)
Learnt about inherited cancer risk during training (yes) 108 (74.0)
Involvement in referral or any part of the process of





Personal or close family member with cancer diagnosis (yes) 52 (35.6)
Personal or close family had a cancer risk assessment (yes) 24 (16.4)
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learnt about inherited cancer risk during training, and
over half were often involved in the referral or another
part of the process of assessing risk for ovarian and/or
breast cancer.
Comparing survey completers and non-completers
It was not possible to calculate a response rate, as the num-
ber of potential participants that the survey invite reached
was not known due to our non-probability sampling
techniques including ‘snowballing’ where existing study
participants recruit others by referring the study on within
their professional network. However, we were able to com-
pare key outcomes between HCPs who completed vs. did
not complete the survey. Fifty-five individuals completed
the self-efficacy questions and 32 completed the knowledge
questions but did not complete the entire survey. The
median score for perceived self-efficacy in conducting a
cancer risk consultation was significantly higher among
those who completed the survey (Mdn = 3.2, IR = 1.0) than
those who did not (Mdn = 3.0, IR = 1.0), U = 4760.0, z =
2.035, p = .042, r = .14. Knowledge of ovarian cancer and
genetics was also significantly higher among survey com-
pleters (Mdn = 7.0, IR = 3.00) than non-completers (Mdn
= 5.0, IR = 3.75), U = 3361.5, z = 3.719, p < .001, r = 0.28.
Self-efficacy in conducting a cancer risk consultation
Table 2 presents participants’ responses to each item meas-
uring self-efficacy. The majority reported feeling ‘quite
confident’ or ‘very confident’ in their abilities across all
aspects of the consultation. The median score for the sam-
ple was 3.2 (IR = 1.0) out of 4, indicating quite high levels
of self-efficacy.
Significant differences in self-efficacy scores were
found between oncologists, genetics specialists, GPs and
gynaecologists, H(3) = 84.273, p < .001. GPs (Mdn = 2.4)
had significantly lower scores than genetics specialists
(Mdn = 3.9, p < .001, r = 1.05), oncologists (Mdn = 3.3,
p < .001, r = 0.60) and gynaecologists (Mdn = 3.1,
p < .001, r = 0.59). Genetics specialists had significantly
higher self-efficacy scores than oncologists (p < .001,
r = −0.46) and gynaecologists (p = .024, r = 0.37). No
significant differences were found between gynaecolo-
gists’ and oncologists’ self-efficacy scores (p > .05). (See
Supplementary File 2, Table S1.)
Knowledge of ovarian cancer and genetics
Table 3 shows the number of correct responses to each
of the knowledge questions for the whole sample and by
HCP group. The median score for the whole sample was
7 (IR = 3.0) out of 8, indicating a high overall level of
knowledge. Questions on the approximate risk of ovar-
ian cancer in women with a BRCA1 or BRCA2 mutation
were most frequently answered incorrectly.
When comparing the knowledge scores of GPs, genetics
clinicians, gynaecologists and oncologists (n = 136), signifi-
cant differences were found, H(3) = 73.233, p < .001. GPs
(Mdn = 4.0) scored significantly lower than genetics clini-
cians (Mdn = 8.0, p < .001, r = 0.97), oncologists (Mdn =
7.0, p < .001, r = 0.61) and gynaecologists (Mdn = 7.0, p
< .001, r = 0.69). It appears that while the majority of GPs
correctly answered 2 non-genetic questions, far fewer cor-
rectly answered the genetics questions. Genetics clinicians
also scored significantly higher than oncologists (p = .004,
r = −0.36). No significant differences were found between
gynaecologists and oncologists, or gynaecologists and gen-
etics clinicians, although for the latter comparison this
may be due to limited power (see Supplementary File 2,
Table S1).
Attitudes (perceived benefits and risks) towards
hypothetical population-based genetic testing for ovarian
cancer risk
Table 4 shows participants’ attitudes toward population-
based genetic testing for ovarian cancer risk. Most HCPs
agreed or strongly agreed that genetic testing would help
identify those with a high risk of ovarian cancer.
Table 2 Self-efficacy in conducting a cancer risk consultation (n = 146)
Not at all confident N (%) Not very confident N (%) Quite confident N (%) Very confident N (%)
Initiate talking to patients about genetic
testing for OC.
2 (1.4) 17 (11.6) 52 (35.6) 75 (51.4)
Record relevant information on a patient’s
family history of cancer.
0 8 (5.5) 55 (37.7) 83 (56.8)
Respond to patients’ questions about OC
risk based on family history.
4 (2.7) 30 (20.5) 60 (41.1) 52 (35.6)
Respond to patients’ questions about genetic
testing for OC risk.
5 (3.4) 28 (19.2) 58 (39.7) 55 (37.7)
Explain lifetime cancer risk to patients. 5 (3.4) 36 (24.7) 50 (34.2) 55 (37.7)
Explain age-related cancer risk to patients. 4 (2.7) 32 (21.9) 69 (47.3) 41 (28.1)
Provide support to patients going through
cancer risk assessment based on family
history and genetic testing.
5 (3.4) 27 (18.5) 64 (43.8) 50 (34.2)
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Participants were also in agreement that this would help
patients make good healthcare decisions about man-
aging their ovarian cancer risk. Less than 50% agreed
that explaining genetic testing to patients would be too
time consuming. However, the majority of participants
believed that genetic testing could have a negative
impact on some patients. In addition, responses were
mixed with regard to whether participants were concerned
that their patients would be discriminated against by in-
surers, and whether population-based genetic testing could
be cost effective.
Willingness to offer population-based genetic testing
Just under half (47.9%) of the HCPs surveyed indicated
that they would be willing to offer all their adult female
patients genetic testing for ovarian cancer risk. A
Table 3 HCP ovarian cancer and genetics knowledge (n = 146)
Total (n = 146) GP (n = 32) Genetics (n = 44) Oncologists (n = 45) Gynaecology (n = 15) Nurse & other (n = 10)
Correctly answered, N (%)
A smear test is not designed to
detect ovarian cancer (True)
143 (97.9) 32 (100.0) 43 (97.7) 44 (97.8) 15 (100) 9 (90.0)
Taking the contraceptive pill can
increase a woman’s risk of
developing ovarian cancer (False)
134 (91.8) 24 (75.0) 43 (97.7) 42 (93.3) 15 (100) 10 (100.0)
The majority of cases of ovarian
cancer are caused by an inherited
genetic mutation (False)
123 (84.2) 13 (40.6) 43 (97.7) 44 (97.8) 15 (100) 8 (80.0)
Paternal family history of cancer is
as important as maternal family
history of cancer when
considering a patient’s risk of
ovarian cancer (True)
108 (74.0) 10 (31.3) 42 (95.5) 37 (82.2) 10 (66.7) 9 (90.0)
A genetic test result that shows a
patient has a variant of uncertain
significance (VUS) indicates that
the patient does not have an
increased risk for ovarian cancer
(False)
111 (76.0) 15 (46.9) 41 (93.2) 32 (71.1) 13 (86.7) 10 (100.0)
The average risk of a women
developing ovarian cancer in her
lifetime is approximately (2%)
115 (78.8) 13 (40.6) 44 (100) 37 (82.2) 14 (93.3) 7 (70.0)
The risk of a woman with a
BRCA1 mutation developing
ovarian cancer in her lifetime is
approximately (30–60%)
102 (69.9) 13 (40.6) 40 (90.9) 32 (71.1) 11 (73.3) 6 (60.0)
The risk of a woman with a
BRCA2 mutation developing
ovarian cancer in her lifetime is
approximately (10–30%)
91 (62.3) 8 (25.0) 36 (81.8) 29 (64.4) 10 (66.7) 8 (80.0)











It would help identify those with a high risk of ovarian cancer. 0 10 (6.8) 17 (11.6) 104 (71.2) 15 (10.3)
My patients could be discriminated against by insurers due to genetic
testing results.
7 (4.8) 38 (26.0) 34 (23.3) 63 (43.2) 4 (2.7)
It could be cost effective in the long term. 1 (0.7) 27 (18.5) 50 (34.2) 57 (39.0) 11 (7.5)
Explaining genetic testing to patients would be too time consuming. 14 (9.6) 65 (44.5) 32 (21.9) 32 (21.9) 3 (2.1)
It would help patients make good healthcare decisions about
managing risk.
1 (0.7) 13 (8.9) 23 (15.8) 99 (67.8) 10 (6.8)
It could have a negative impact on some of my patients. 1 (0.7) 16 (11.0) 21 (14.4) 94 (64.4) 14 (9.6)
Willingness to offer population-based genetic testing
I would be willing to offer all my adult female patients genetic testing
for OC risk.
8 (5.5) 33 (22.6) 35 (24.0) 53 (36.3) 17 (11.6)
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significant difference was found between oncologists,
genetics clinicians, GPs and gynaecologists responses to
this item, F(6) = 42.204, p < .001 (see Additional file 2
Table S2). Compared to genetics clinicians (18.2%), sig-
nificantly more oncologists (68.9%) and GPs (50.0%)
agreed with the statement ‘I would be willing to offer all
my adult female patients genetic testing for ovarian can-
cer risk’. No significant difference was found between
groups for the neutral response to this item. These re-
sults suggest that genetics clinicians were the least will-
ing to offer genetic testing for ovarian cancer risk to all
their adult female patients.
Beliefs about ovarian cancer low, intermediate and high
risk boundaries
Participants gave a variety of responses when asked to
indicate what they thought the boundaries for ‘low risk’,
‘intermediate risk’ and ‘high risk’ for ovarian cancer are.
The mode upper boundary for ‘low risk’ of ovarian can-
cer was 5% risk, however this response was only given
by 37.7% of the sample and responses ranged from as
low as 0% to 10%. The mode lower boundary for ‘high
risk’ of ovarian cancer was 10% risk, which was the re-
sponse of 39.0% of the sample, responses ranged widely
from 5% up to 70%. The most frequently referred to
boundaries for ‘intermediate risk’ was 5–10% risk, and
responses ranged from 1 to 2% to 30–50% risk. The re-
sults indicate that the majority of participants’ percep-
tions of risk were not in-line with the clinically-
informed boundaries adopted for the PROMISE feasi-
bility study.
Attitudes (perceived benefits and risks) towards risk
stratification for ovarian cancer
Table 5 shows participants’ attitudes towards risk
stratification for ovarian cancer. While the majority
agreed that risk stratification for ovarian cancer would
help identify those most in need of screening, ap-
proximately 80% also agreed that it would lead to
ovarian cancer being missed in some patients.
Participants had mixed views on how patients
would react to being stratified by risk. Over 60% of
the sample indicated that risk stratification would give
patients a sense of control. Only 6.7% of participants
believed risk stratification would cause patients to feel
fatalistic about their health, although 53% were un-
sure. Most participants agreed that patients would
feel reassured if stratified into a low risk group; fewer
than half indicated that this would give patients a
false sense of security. Fewer than half believed that
being stratified into a high risk group or an inter-
mediate risk group would have a negative impact on
patients’ emotional well-being.
Most participants indicated that they would feel
confident in explaining what ‘low risk’ (88.3% agreed/
strongly agreed), ‘intermediate risk’ (83.6% agreed/
strongly agreed) and ‘high risk’ means to patients
(87.7% agreed/strongly agreed) (after they had been











RS would help identify those most in need of screening for ovarian
cancer.
1 (0.7) 7 (4.8) 7 (4.8) 115 (78.8) 16 (11.0)
RS would lead to ovarian cancer being missed in some patients. 0 9 (6.2) 20 (13.7) 112 (76.7) 5 (3.4)
RS would give patients a sense of control over their health. 0 5 (3.4) 48 (32.9) 88 (60.3) 5 (3.4)
RS for ovarian cancer would make patients feel fatalistic about
their health
2 (1.4) 57 (39.0) 77 (52.7) 10 (6.8) 0
Stratification into low risk would give a false sense of security. 2 (1.4) 38 (26.0) 40 (27.4) 65 (44.5) 1 (0.7)
Stratification into a low risk group would be reassuring. 0 13 (8.9) 28 (19.2) 104 (71.2) 1 (0.7)
Stratification into a group at high risk would have a negative
impact on well being
1 (0.7) 31 (21.2) 51 (34.9) 59 (40.4) 4 (2.7)
Stratification into a group at intermediate risk would have a
negative impact on well being
2 (1.4) 28 (19.2) 66 (45.2) 49 (33.6) 1 (0.7)
Stratification into a group at low risk would have a negative
impact on well being
9 (6.2) 104 (71.2) 29 (19.9) 4 (2.7) 0
Risk stratification consultation (communication) self-efficacy.
I am confident I could explain what ‘low risk’ means to patients
in that group
0 7 (4.8) 10 (6.8) 97 (66.4) 32 (21.9)
I am confident I could explain what ‘intermediate risk’ means to
patients in that group
0 9 (6.2) 15 (10.3) 93 (63.7) 29 (19.9)
I am confident I could explain what ‘high risk’ means to patients in
that group
0 6 (4.1) 12 (8.2) 94 (64.4) 34 (23.3)
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informed of the risk boundaries as set for the PROM-
ISE feasibility study; see Supplementary File 1).
Willingness to tailor patient management according to
risk stratification based recommendations: Closed-ended
questions
The majority of participants reported that they would
be willing (probably or definitely) to discuss the sug-
gested stratified interventions: 88.3% were willing to
discuss information with those at low risk, 85.0% and
82.2% were willing to discuss screening (CA125 blood
test every 4 months and an annual ultrasound scan)
with patients at intermediate and high risk respect-
ively, and 84.3% and 90.4% were willing to discuss
surgery with intermediate and high risk patients re-
spectively (see Additional file file 2: Table S3).
Reasons for being willing/not willing to tailor patient
management according to risk stratification-based recom-
mendations: Open-ended questions
The optional free-text responses giving reasons for will-
ingness to discuss the various interventions were approxi-
mately one or two sentences in length and were provided
initially by 121 participants. Frequently reported reasons
for being unwilling to discuss information with low risk
patients were practical, such as lack of time and resources.
Reticence about discussing screening with patients was
mostly because it has not yet been shown to be effective,
while reluctance to discuss surgery was due to some HCPs
not considering this to be part of their job.
The most frequently given reasons for willingness to
discuss symptom awareness and providing lifestyle ad-
vice was that this capitalised on a health promotion op-
portunity and would be useful for patients. Willingness
to discuss screening was often described as being part of
their job and they already offered similar tests to pa-
tients. Willingness to discuss surgery with patients was
underpinned by the belief that it would benefit patients
by reducing risk and preventing ovarian cancer. Several
participants gave ‘conditional’ responses, for example
they would discuss screening with patients if evidence
proved its effectiveness or they would discuss surgery
depending on patient characteristics such as age. See
Additional file file 2: Tables S4 and S5 for a full list of
the themes identified from participants’ responses, sup-
porting quotes, and the number of times these themes
appeared.
Discussion
This study examined UK HCPs’ knowledge of ovarian
cancer and genetics, their self-efficacy in conducting a
cancer risk consultation, and their attitudes towards a
programme using population-based genetic testing and
risk stratified management for ovarian cancer. Survey re-
sponses reflected what the practitioners anticipated they
would do in specific situations, not their actual practices.
Overall, participants’ knowledge of ovarian cancer and
related genetics was high and this was reflected in clini-
cians’ belief that they could effectively conduct a cancer
risk consultation. However, substantial differences in
knowledge were identified between the various special-
ists, with lower scores for GPs. This pattern of results is
consistent with previous research in Europe and the US
indicating lower knowledge of genetics among primary
HCPs compared to more specialised HCPs [15, 19, 20].
The GPs’ results are similar to an earlier report [14] that
56.9% of primary care physicians knew that the majority
of ovarian cancer cases are sporadic and 34.5% knew
that maternal history was not more important than pa-
ternal history when considering cancers that mostly
affect women, compared to 40.6and 31.3% of GPs in the
current study. Significant differences between HCP disci-
plines were also identified regarding self-efficacy to con-
duct a cancer risk consultation, and GPs were again
found to have lower scores. Despite this, the results indi-
cate that the majority of participants were at least “quite
confident” in their ability to record relevant information
on patients’ family history of cancer, an improvement on
findings from earlier research on recording family histor-
ies of disease [17, 28].
These results are perhaps unsurprising since GPs deal
with a wide variety of health conditions, whilst genetics
clinicians, oncologists, and gynaecologists have specialist
training in genetics and/or cancer. Nonetheless, the find-
ings highlight the need to improve GPs’ knowledge of
ovarian cancer genetics and self-efficacy in discussing
genetics and risk with patients for the successful intro-
duction of population-based genetic testing for ovarian
cancer risk in the UK. If genetic testing were offered
clinically on a population basis it would be important for
those found to be carrying a BRCA gene mutation or
with a strong family history of cancer to receive counsel-
ling by genetics specialists. The service delivery model
will need to be worked out, but primary care providers
may well be responsible for ensuring patients from the
general population (without a cancer diagnosis) make an
informed decision about undergoing genetic testing, and
in the ensuing risk assessment and stratification pro-
cesses. HCPs including GPs will need to have a broad
understanding of genetics and cancer, be able to record
patient family history and lifestyle factors, use risk tools,
interpret risk and communicate risk in a jargon-free
manner. Furthermore, they will need to be aware of and
able to manage patient anxieties and offer appropriate
risk management options [34].
In parallel with improving the skills and knowledge of
non-genetics clinicians and due to time pressures, tools
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such as decision aids could be useful for helping patients
reach informed decisions about whether to have a cancer
risk assessment and their risk management options. De-
cision aids (e.g. leaflets, websites) can increase patient
knowledge about treatment options and can be more ef-
fective than usual care (such as having an appointment
with a HCP alone) [35, 36]. Decision aids, which provide
information and help patients to consider their personal
values in relation to a health decision, can also help
manage expectations and reduce decisional conflict [35].
Attitudes towards population-based genetic testing for
ovarian cancer risk were mixed in the present study.
While the majority of HCPs acknowledged the potential
benefits for patients, several felt that genetic testing
could negatively impact some patients and nearly half
believed patients could be discriminated against by in-
surers based on test results; these findings are in line
with previous research, although to a lesser extent [27,
37]. Since 2001, the Concordat and Moratorium (in
place until November 2019) [38] has protected the inter-
ests of insurers and patients in the UK. These agree-
ments, put together by the Government and the
Association of British Insurers, stipulate that patients
who have undergone predictive genetic testing do not
have to reveal test results to insurers unless applying for
life insurance over £500,000 or testing for Huntington’s
disease. It is possible that HCPs are not aware of this
agreement or that they anticipate that in the future it
will change and potentially no longer provide the same
protection to patients.
Importantly, fewer than half of the HCPs surveyed
agreed that they ‘would be willing to offer all my adult pa-
tients genetic testing for ovarian cancer risk’. Of particular
note is that, only 18% of genetics specialists agreed with
this statement. Their reservations about testing may be
because their professional knowledge makes them acutely
aware that genetic tests may generate variants of unknown
significance (VUS). A VUS is a change in the gene se-
quence where any association with an increased cancer
risk is unclear or unknown. It is estimated that around 1
in 20 of BRCA1 and BRCA2 full screens in UK regional
genetics laboratories will result in a VUS being identified
[39]. Given that the chance of identifying a pathogenic
mutation in full BRCA1 and BRCA 2 screening in the UK
population is around 1 in 400, it is more likely that a VUS
will be found if population testing is adopted [40]. Whilst
international efforts to better characterise VUSs will likely
result in the VUS rate decreasing in BRCA1 and BRCA2,
this is likely to take longer for other, less well charac-
terised, genes such as RAD51 C and D and BRIP1. Here
the VUS rate may remain significant, making advice to
families difficult. The other concern for geneticists is that
mutations identified on a population rather than family
history basis, may have lower penetrance. Again, this
raises difficulties in quantifying ovarian cancer risk and for
subsequent management advice. For example, the BRCA1
R1699Q variant [41] appears to be a low-moderate pene-
trance BRCA1 mutation, necessitating different risk man-
agement advice. Geneticists may also be more cautious
because of the possibility of unintentionally identifying
gene changes that increase the risk of diseases other than
ovarian cancer. These incidental findings can arise as a re-
sult of the technologies used in population based panel
testing. Furthermore, compared to many other HCPs, ge-
neticists care for families rather than individuals and are
cognizant of the implications of genetic test results for
family members, as well as for the patient. Traditionally,
genetic counselling has been attuned to the psychosocial
as well as medical aspects of a patient’s care, and there is
an awareness of the potential adverse psychological out-
comes in patients who have a “bad news” predictive gen-
etic test result [42, 43].
Increasingly, genetic testing is offered within gynae-
oncology services to ovarian cancer patients with high-
grade non-mucinous ovarian cancer, irrespective of their
family history of cancer. Evidence suggests that this ‘main-
stream’ approach is effective at identifying gene carriers
who would not otherwise have been tested [44]. The will-
ingness amongst oncologists to offer population-based
genetic testing to all adult female patients may reflect the
move towards mainstreaming BRCA1/2 genetic testing
within ovarian cancer care. Further work is needed to clar-
ify the factors influencing UK HCPs’ willingness to offer
population-based genetic testing.
Attitudes towards risk stratification for ovarian cancer
were also mixed, though generally positive. Most partici-
pants agreed that risk stratification would help identify
those most in need of screening and would give patients a
sense of control over their health. They disagreed that risk
stratification would make patients feel fatalistic about their
health and over half did not agree that stratification into a
low risk group would give patients a false sense of secur-
ity, which accords with the views of women in previous
studies [45]. Our finding that fewer than half of the HCPs
believed that stratification into a high or intermediate risk
group would have a negative impact on patients’ well-
being may reflect awareness that patients who undergo
genetic testing for cancer risk do not tend to experience
adverse psychological consequences in the long-term [46].
Whilst most participants’ perceptions of low, intermedi-
ate and high risk boundaries were found to initially not be
in line with those set by the PROMISE feasibility study,
after revealing these boundaries the majority of HCPs sur-
veyed reported that they would be confident in explaining
what low, intermediate and high risk meant to patients in
those groups. Although other research has found that on-
cologists and surgeons feel confident in reporting risk to
patients [47], Nippert et al. [4] report in their European
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survey that most UK based GPs felt genetic specialists
should explain genetic test results to patients. The commu-
nication of a health risk to patients with low health literacy
or poor numerical skills can be particularly difficult [48].
The majority of participants indicated that, if population
based risk assessment and stratification were offered, they
would be willing to discuss symptom awareness and life-
style advice with low risk patients, and screening and sur-
gery with intermediate and high risk patients. Some
identified a need for training and guidance. Willingness to
discuss screening tests (CA125 blood tests and scans of
the ovaries) with intermediate and high risk patients may
reflect familiarity with their use as diagnostic tests for
ovarian cancer. Some participants indicated they would
not be willing to discuss ovarian cancer screening because
it has not been shown to save lives, whereas others indi-
cated willingness to discuss it on the condition that it is
proven to be effective. These findings are unsurprising
considering the publication of mortality results from the
UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) just a few months prior to the survey going
live. Results from the randomised-controlled trial indi-
cated that ovarian cancer screening using CA125 (inter-
preted with the ROCA) and ultrasound scans in a general
population sample of post-menopausal women show high
sensitivity, specificity, acceptability, and compliance, but at
initial reporting the mortality impact did not reach statis-
tical significance [2]. Recent results from the second phase
of the UKFOCSS [13] were not available at the time of the
survey and therefore will not have influenced the views of
our survey participants. This trial found that ROCA-based
screening for ovarian cancer of women at high risk (≥10%
risk) was highly sensitive and resulted in a stage shift, indi-
cating that it could be provided as an option to women
who are not yet ready to undergo prophylactic surgery.
However, the mortality impact could not be assessed as
this was not a randomised trial with a control arm.
Recent studies suggest that risk-reducing bilateral
salpingo-oophorectomy (RRSO) would be cost effective in
postmenopausal women at ≥5% risk and premenopausal
women over 40 years of age at ≥4% risk [49, 50]. Current
UK practice is that women with a lifetime risk for ovarian
cancer ≥10%, who have completed childbearing can be of-
fered RRSO between age 35–40 years [51]. Interestingly,
the majority of HCPs in the current study indicated that
they would be willing to discuss RRSO with women at
‘intermediate risk’ of ovarian cancer (5–9.9% risk), al-
though some explained that this discussion would be
dependent on characteristics of the patient (e.g. age) or
medical guidelines. Current guidelines [52, 53] indicate
that RRSO may be considered for women who carry mu-
tations in intermediate risk genes e.g. RAD51 and BRIP1
between age 45–50 or earlier. Only two participants indi-
cated they would not be willing to discuss surgery with
women at ‘intermediate risk’ as they felt RRSO was only
appropriate for high risk women. However, the results re-
flect what HCPs anticipate they would do in a hypothet-
ical scenario, rather than their actual actions or current
practice. Further work is needed to tease out HCPs views
of RRSO in women with a lower than 10% risk of ovarian
cancer, as willingness to discuss RRSO with ‘intermediate
risk’ patients may reflect a lack of knowledge of the
current conditions under which RRSO is offered. This is
particularly pertinent for genes such as RAD51 and
BRIP1, where the risk may be 5–10%.
The small sample size of this survey study restricted the
inter group comparisons and the ability to control for
confounding factors. Comparisons could not be made on
the demographics of those who completed and did not
complete the survey (those who did not complete the sur-
vey did not answer the demographic questions). Due to
the small sample size and because participants were active
members of professional organisations, our findings may
not extend to the wider HCP community. Our partici-
pants are likely to have better knowledge of, interest in,
and professional experience with ovarian cancer and gen-
etics. Furthermore, as the study was conducted with HCPs
in the UK the results cannot be generalised to HCPs
working in other countries where healthcare systems and
genetic services are different. Finally, due to the methods
of recruitment used it was not possible to calculate a re-
sponse rate for this study. Despite these limitations, sig-
nificant differences were detected between the different
HCP groups, and fewer than half the participants stated
that they would be willing to offer all female patients gen-
etic testing for ovarian cancer risk, thus providing poten-
tially important insights and testable hypotheses for future
research.
Conclusion
To our knowledge, this is the first UK survey of HCPs’
attitudes towards a programme using population-based
genetic testing and stratified interventions for ovarian
cancer. It provides novel insights into the acceptability
of such a programme. If risk assessment and stratified
management are to be used more widely to help im-
prove early detection of ovarian cancer, more research is
needed to identify potential barriers to their provision by
HCPs and training needs.
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